From the Abstract for this August 2020 JAMA Ophthalmology medical journal article, “Retinal Vasculitis After Administration of Brolucizumab Resulting in Severe Loss of Visual Acuity”, we get the following five facts concerning a Beovu retinal vasculitis case report:
- A 77-year-old woman had acute visual acuity loss in her right eye following her second administration of [Beovu (brolucizumab)] for neovascular age-related macular degeneration.
- She had previously been treated with both [Avastin (bevacizumab)] and [Eylea (aflibercept)] since her initial diagnosis in 2018. She had never had any intraocular inflammation with either medication.
- Her baseline visual acuity was 20/50 OD and 20/30 OS.
- She initially noted blurry vision immediately after her injection with [Beovu (brolucizumab)] but believed it would be temporary. She presented to the office 3 weeks later, on her return from a cruise. Her visual acuity was 20/200 OU.
- Her left eye was unremarkable.
Beovu was approved by the FDA in 2019 for the treatment of neovascular (wet) age-related macular degeneration (AMD). Since then there have been reports of Beovu-associated vision loss and blindness due to occlusive retinal vasculitis, retinal artery occlusion, and intraocular inflammation.
We will continue to monitor the medical literature for reports of retinal vasculitis with Beovu use as well as cases of acute visual acuity loss involving Beovu.[View article in full at original source]